Lakewood-Amedex Biotherapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LABT | -80.17% | — | — | — |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -83.14% | — | — | — |